Intellipharmaceutics International Past Earnings Performance
Past criteria checks 0/6
Intellipharmaceutics International has been growing earnings at an average annual rate of 35.8%, while the Pharmaceuticals industry saw earnings growing at 59.3% annually. Revenues have been declining at an average rate of 43.4% per year.
Key information
35.8%
Earnings growth rate
74.2%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | -43.4% |
Return on equity | n/a |
Net Margin | -350.7% |
Last Earnings Update | 31 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Intellipharmaceutics International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Aug 23 | 1 | -3 | 1 | 2 |
31 May 23 | 1 | -2 | 0 | 2 |
28 Feb 23 | 0 | -2 | 0 | 2 |
30 Nov 22 | 0 | -3 | 1 | 2 |
31 Aug 22 | 0 | -4 | 1 | 3 |
31 May 22 | 0 | -5 | 1 | 3 |
28 Feb 22 | 0 | -5 | 1 | 3 |
30 Nov 21 | 0 | -5 | 1 | 3 |
31 Aug 21 | 0 | -5 | 1 | 3 |
31 May 21 | 1 | -3 | 2 | 3 |
28 Feb 21 | 1 | -3 | 2 | 3 |
30 Nov 20 | 1 | -3 | 2 | 4 |
31 Aug 20 | 1 | -3 | 2 | 4 |
31 May 20 | 3 | -6 | 3 | 4 |
29 Feb 20 | 4 | -7 | 3 | 5 |
30 Nov 19 | 3 | -8 | 4 | 7 |
31 Aug 19 | 4 | -11 | 5 | 8 |
31 May 19 | 2 | -13 | 4 | 10 |
28 Feb 19 | 2 | -14 | 4 | 11 |
30 Nov 18 | 2 | -14 | 3 | 11 |
31 Aug 18 | 2 | -12 | 4 | 10 |
31 May 18 | 3 | -11 | 4 | 9 |
28 Feb 18 | 5 | -10 | 3 | 10 |
30 Nov 17 | 6 | -9 | 3 | 9 |
31 Aug 17 | 5 | -10 | 3 | 10 |
31 May 17 | 4 | -10 | 4 | 10 |
28 Feb 17 | 3 | -10 | 4 | 10 |
30 Nov 16 | 2 | -10 | 4 | 8 |
31 Aug 16 | 3 | -9 | 3 | 5 |
31 May 16 | 3 | -9 | 3 | 3 |
29 Feb 16 | 4 | -9 | 3 | 0 |
30 Nov 15 | 4 | -7 | 4 | 7 |
31 Aug 15 | 5 | -6 | 4 | 0 |
31 May 15 | 5 | -5 | 4 | 0 |
28 Feb 15 | 5 | -7 | 4 | 0 |
30 Nov 14 | 9 | -4 | 4 | 0 |
31 Aug 14 | 9 | -9 | 4 | 0 |
31 May 14 | 8 | -9 | 3 | -2 |
28 Feb 14 | 6 | -8 | 3 | 0 |
30 Nov 13 | 2 | -11 | 3 | 0 |
Quality Earnings: IPCI.H is currently unprofitable.
Growing Profit Margin: IPCI.H is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IPCI.H is unprofitable, but has reduced losses over the past 5 years at a rate of 35.8% per year.
Accelerating Growth: Unable to compare IPCI.H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPCI.H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: IPCI.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.